2023 shaping up to be biggest year for biopharma M&A since pandemic

seekingalpha2023-08-07

The IPO market may still be frigid, but 2023 is shaping up to be the biggest year for biopharma M&A since the pandemic, despite rising capital costs and increased scrutiny by antitrust regulators. The...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2357473783?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1347295696/image_1347295696.jpg","is_english":true,"pubTime":"2023-08-07 03:35","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2357473783","market":"us","top_or_hot":-1,"title":"2023 shaping up to be biggest year for biopharma M&A since pandemic","media":"seekingalpha","content":"<div>\n<p>The IPO market may still be frigid, but 2023 is shaping up to be the biggest year for biopharma M&A since the pandemic, despite rising capital costs and increased scrutiny by antitrust regulators. The...</p>\n\n<a href=\"https://seekingalpha.com/news/3997958-2023-shaping-up-to-be-biggest-year-for-biopharma-ma-since-pandemic\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2023 shaping up to be biggest year for biopharma M&A since pandemic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2023 shaping up to be biggest year for biopharma M&A since pandemic\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-07 03:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3997958-2023-shaping-up-to-be-biggest-year-for-biopharma-ma-since-pandemic><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market may still be frigid, but 2023 is shaping up to be the biggest year for biopharma M&A since the pandemic, despite rising capital costs and increased scrutiny by antitrust regulators. The...</p>\n\n<a href=\"https://seekingalpha.com/news/3997958-2023-shaping-up-to-be-biggest-year-for-biopharma-ma-since-pandemic\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0861579265.USD","symbol_name":"联博低波幅策略股票基金A","start_time":0,"source_url":"https://seekingalpha.com/news/3997958-2023-shaping-up-to-be-biggest-year-for-biopharma-ma-since-pandemic","article_id":"2357473783","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1347295696/image_1347295696.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2357473783","pubTimestamp":1691350500,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"The IPO market may still be frigid, but 2023 is shaping up to be the biggest year for biopharma M&A since the pandemic, despite rising capital costs and increased scrutiny by antitrust regulators. The","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0861579265.USD":"联博低波幅策略股票基金A","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC",".IXIC":"NASDAQ Composite","QID":"纳指两倍做空ETF","BK4581":"高盛持仓","PSQ":"纳指反向ETF","RETA":"Reata制药","SQQQ":"纳指三倍做空ETF","SG9999001176.USD":"United Global Healthcare Acc USD","PFE":"辉瑞","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4548":"巴美列捷福持仓","TQQQ":"纳指三倍做多ETF","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","AMGN":"安进","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4516":"特朗普概念","KVUE":"Kenvue Inc","KDNY":"Chinook Therapeutics, Inc.","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","HZNP":"Horizon Pharma","QQQ":"纳指100ETF","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BIIB":"渤健公司","BK4139":"生物科技","MRK":"默沙东","LU0234572021.USD":"高盛美国核心股票组合Acc","NVS":"诺华","SG9999002232.USD":"Allianz Global High Payout USD","ILMN":"Illumina","BK4578":"CAR-T","QLD":"纳指两倍做多ETF","LU0058720904.USD":"联博国际健康护理基金A","SGEN":"Seagen","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","BK4568":"美国抗疫概念"},"translate_title":"2023年将成为疫情以来生物制药并购规模最大的一年","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1,"KVUE.WI":1,"KVUE":1,"KDNY":1,"ILMN":1,"MRK":1,"NVS":1,"PFE":1,"HZNP":1,"RETA":1,"SGEN":1,"BIIB":1,".IXIC":0.77,"QQQ":0.6,"TQQQ":0.6,"SQQQ":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"The IPO market may still be frigid, but 2023 is shaping up to be the biggest year for biopharma M&A since the pandemic, despite rising capital costs and increased scrutiny by antitrust regulators. The sector has already seen $80B in deals this year, including a $43B planned takeover of Seagen (NASDAQ:SGEN) by Pfizer (NYSE:PFE). For comparison, 2022 saw $96B in M&A deals, while 2021 saw $91B and 2020 had $131B, according to a report by Evaluate Pharma. One driver has been a downward shift in biotech valuations, with the Nasdaq Biotech Index slipping 3.38% since the beginning of the year and the SPDR S&P Biotech ETF declining 2.14%, after seeing records highs in 2021. Another has been the IPO market, which despite showing signs of thawing remains largely frozen for many companies. While several of the biggest IPOs this year have been the healthcare space, including Kenvue's (KVUE) $3.8B debut, activity has declined sharply since 2021, making biotechs more open to deals. How attractive a company is as a takeover target, however, could be impacted by the Inflation Reduction Act, which empowers the US government to negotiate drug prices for the massive Medicare program.  According to Evaluate Pharma, some experts have speculated the proposed price controls will favor biologics rather that small molecule drugs. Multi-use therapies, even those used to treat rare disorders, might also be viewed as less attractive than those approved for just one indication.  Another factor is the Federal Trade Commission, which has been increasingly critical of deals they view as anti-competitive. The watchdog agency has voiced antitrust concerns about Amgen's (NASDAQ:AMGN) proposed $28B takeover of Horizon (NASDAQ:HZNP) and recently ordered Illumina (ILMN) to unwind its $7B merger with GRAIL.  Despite the agency's tougher stance on major mergers in the sector, the FTC appears to have adopted a more benign view of takeovers involving smaller players, especially those with limited financial resources. In a recent note, Cantor Fitzgerald noted that FTC Chair Lina Khan was quoted recently saying that companies with development-stage or recently launched drugs that may need be acquired to reach the commercialization stage provide \"a very different set of facts than instances in which we see acquisitions of existing blockbuster drugs.\" Cantor said that they believe Khan's remarks could imply that deals involving takeover targets with \"first-in-class\" drugs, such as Biogen's (BIIB) $7B deal with Reata (RETA), or those with pre-commercial assets may face less FTC scrutiny than those involving established products. \"We are curious to see if this may factor into the shopping considerations of big pharma towards later-stage clinical or early commercial companies to reduce FTC risks,\" Cantor added. During the first half of the year, 12 deals priced over $1B, including eight during Q2. Top of the list for Q2 is Merck's (MRK) takeover of Prometheus Biosciences for $10.8B, following by Astellas's (OTCPK:ALPMF) proposed acquisition of Iveric Bio for $5.9B and Novartis's (NVS) planned merger with Chinook Therapeutics (KDNY) for $3.2B, according to Evaluate Pharma. More on Big Pharma M&A: Amgen says FTC has ignored commitments it made to address Horizon deal concerns Seagen, Pfizer get second info request from FTC on $43B merger deal Illumina fined $475M in EU for closing GRAIL acquisition Illumina ordered by FTC to divest GRAIL over competition concerns","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2357473783"}